CN105535171A - Rose tea - Google Patents
Rose tea Download PDFInfo
- Publication number
- CN105535171A CN105535171A CN201610145262.6A CN201610145262A CN105535171A CN 105535171 A CN105535171 A CN 105535171A CN 201610145262 A CN201610145262 A CN 201610145262A CN 105535171 A CN105535171 A CN 105535171A
- Authority
- CN
- China
- Prior art keywords
- parts
- rose tea
- tea
- thousand
- pagoda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides rose tea prepared from raw materials in parts by weight as follows: 18-22 parts of roses, 16-22 parts of Stephania sinica Diels, 10-16 parts of Crossostephium chinense, 20-30 parts of Caryopteris incana Miq and 10-14 parts of Wrightia roots or stems; the raw materials are dried, crushed, evenly mixed and bagged to be produced into teabags with a conventional teabag production technology. The rose tea has the function of resisting Helicobacter pylori.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicine preparation, be specifically related to a kind of rose tea.
Background technology
Helicobacter pylori (Helicobacterpylori, Hp) is a kind of Gram-negative spiral bacteria.Research display, helicobacter pylori is the primary pathogenic event of acute and chronic gastritis and taste-blindness rate, and may fall ill relevant with gastric cancer stomach function regulating mucosa-associated lymphoid tissue (MALT) malignant lymphoma.Recently, Hp is classified as I class carcinogen by World Health Organization (WHO), and it plays a leading role in stomach cancer development.Simultaneously the scheme that popular at present treatment Hp infects takes the triple therapy that proton pump inhibitor (PPI) adds two kinds of antibiotic (clarithromycin, amoxicillin, tetracycline, metronidazole etc. select two kinds).The main factor affecting triple therapy is considered to the drug resistance of Hp to antibacterial; Another serious problems are that proton pump inhibitor can bring out dyspepsia, and a large amount of antibacterial then causes the serious destruction of flora in digestive tract.Therefore, find the active kind new medicine thing of efficient, safe anti-Hp and become an important and urgent task.
Summary of the invention
Goal of the invention: in order to solve the problem, the object of the present invention is to provide a kind of rose tea and application.
Technical scheme: the object of the invention is by following scheme realize:
A kind of rose tea, it is prepared by the raw material of following parts by weight: Flos Rosae Rugosae 18-22 part, Radix Stephaniae Japonicae 16-22 part, Chinese mugwort 10-16 part, pagoda in thousand spend 20-30 part, Radix seu caulis wrightiae pubescentis 10-14 part, drying, pulverizing, and mix homogeneously, adopt conventional production process of bagged tea again, teabag is made in pack.
Described rose tea, it is prepared by the raw material of following parts by weight: Flos Rosae Rugosae 120 parts, Radix Stephaniae Japonicae 18 parts, Chinese mugwort in thousand 14 parts, pagoda spends 25 parts, Radix seu caulis wrightiae pubescentis 12 parts, drying, pulverizing, and mix homogeneously, adopt conventional production process of bagged tea again, teabag is made in pack.
The application in Anti-helicobacter pylori drugs prepared by described rose tea.
Flos Rosae Rugosae is the flower of rosaceous plant Flos Rosae Rugosae and polyphyll Flos Rosae Rugosae.
Radix Stephaniae Japonicae, formal name used at school: StephaniasinicaDiels is a kind under Stephania.Heat-clearing and toxic substances removing, eliminating stasis to stop pain.For upper respiratory tract infection, pharyngolaryngitis, stomachache, acute gastroenteritis, bacillary dysentery, malaria, rheumatalgia, trauma pain; Traumatic injury is controlled in external, venom, sore swollen toxin.The present invention is with all herbal medicine.
Within thousand, Chinese mugwort is Compositae Hibisci Mutabilis Dendranthema Chinese mugwort Crossostephiumchinense (L.) Makino in thousand, is used as medicine with root, leaf.The whole year can adopt, and cleans, using fresh herb or dry.Expelling wind and removing dampness, removing toxic substances and promoting subsidence of swelling, relieving cough and resolving phlegm.For anemofrigid cold, measles, Fengshi Guanjie pain, stomachache, bronchitis, pertussis, furuncle swelling toxin, mastitis.The present invention is used as medicine with leaf.
Pagoda flower is the herb of labiate C. gracile Clinopodiumgracile (Benth.) Matsumra.Dispelling wind to relieve the exterior syndrome, expelling phlegm for arresting cough, scattered silt pain relieving.For upper respiratory tract infection, pertussis, bronchitis, rheumatic arthritis, gastroenteritis, treating swelling and pain by traumatic injury, puerperal abdominalgia with blood stasis; Venom is controlled in external, eczema, skin itching.
Radix seu caulis wrightiae pubescentis is root or the stem branch that apocynaceae plant hangs upside down pen.Latin name: WrightiapubescensR.Br., the whole year all can adopt, and cleans, and section, dries.Dispelling wind and removing obstruction in the collateral; Dissipating phlegm and resolving masses; Dampness removing.Main air pain of dampness syndrome; Lumbocrural pain; Traumatic injury; Scrofula; Chronic bronchitis; Icterohepatitis, cirrhotic ascites.The present invention is used as medicine with root.
Beneficial effect:
From theory of Chinese medical science, in we, Radix Stephaniae Japonicae, Chinese mugwort heat-clearing and toxic substances removing, expelling wind and removing dampness in thousand are monarch drug, and pagoda flower, Radix seu caulis wrightiae pubescentis dissipating phlegm and resolving masses are ministerial drug, and increase monarch drug effect, Flos Rosae Rugosae is adjuvant, coordinating the actions of various ingredients in a prescription, and all medicines are harmonious, and play anti-helicobacter pylori activity altogether.Formulation of the present invention is reasonable, and compatibility is rigorous.The present invention consists of Chinese crude drug, has no side effect, low price.
Detailed description of the invention
Form by the following examples, foregoing of the present invention is described in further detail again, but this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following example, all technology realized based on foregoing of the present invention all belong to scope of the present invention.
Embodiment 1: get Flos Rosae Rugosae 18 parts, Radix Stephaniae Japonicae 22 parts, Chinese mugwort in thousand 10 parts, pagoda spends 30 parts, Radix seu caulis wrightiae pubescentis 10 parts, drying, pulverizing, and mix homogeneously, then adopt conventional production process of bagged tea, teabag is made in pack.
Embodiment 2: get Flos Rosae Rugosae 22 parts, Radix Stephaniae Japonicae 16 parts, Chinese mugwort in thousand 16 parts, pagoda spends 20 parts, Radix seu caulis wrightiae pubescentis 14 parts, drying, pulverizing, and mix homogeneously, then adopt conventional production process of bagged tea, teabag is made in pack.
Embodiment 3: get Flos Rosae Rugosae 12 parts, Radix Stephaniae Japonicae 18 parts, Chinese mugwort in thousand 14 parts, pagoda spends 25 parts, Radix seu caulis wrightiae pubescentis 12 parts, drying, pulverizing, and mix homogeneously, then adopt conventional production process of bagged tea, teabag is made in pack.
Embodiment 4: pharmacological evaluation of the present invention
1) strains tested: helicobacter pylori (Helicobacterpylori, Hp) reference culture ATCC43504 is purchased from U.S.'s Culture Collection (AmericanTypeCultureCollection, ATCC).15 strain Hp clinical strains are picked up from Jiangsu Prov. People's Hospital Gastroenterology dept., clinical laboratory of Jiangsu TCM Hospital and Nanjing Children's Hospital Dndoscope Laboratory and are accepted gastroscopic patient; To the patient of peptic ulcer, duodenal bulbar inflammation or gastritis verrucosa in continuous gastroscopy, first be defined as Hp positive through RUT experiment, get antral gastric mucosa 1-2 block again, be inoculated in containing 8% horse serum, trimethoprim (trimethropin after chopping, in the Columbia selectivity agar culture medium of TMP) 1.25g/L, polymyxin (polymyxin) B2500U/L, vancomycin (vancomycin) 10mg/L, in 37 DEG C under micro-oxygen environment (5%O2,10%CO2 and 85%N2) cultivate 72 hours.Collect antibacterial, through smear Gram’s staining, after oxidase, catalase and urease are accredited as the positive, pure culture of going down to posterity, obtained strains is as experimental strain.
2) strain culturing: we adopt micro-aerobic bag (purchased from Shanghai Medical Univ) to carry out the strain culturing of HP, it produces the micro-aerobic environment required for Hp by chemical reaction.
3) test drug is prepared according to the method for above-described embodiment 1.
4) biological activity determination: adopt paper disk method (Microbiologicalpapermethod) to measure the inhibitory action of compound to helicobacter pylori, the minimum inhibitory concentration (minimalinhibitoryconcentration, MIC) of test sample is measured with agar dilution.
I. paper disk method experiment: (A) prepares culture medium by the Columbia culture medium for preparing after high pressure steam sterilization, be cooled to 50-60 DEG C, add 8% horse serum or Sheep Blood, mixing is poured in the culture dish of sterilizing, every ware 7-10ml, culture medium thickness is 1.5mm (sterile working).(B) experimental bacteria of transferring (being coated with bacterium) gets 108CFU/ml (1OD660=108CFU/ml) Hp diluted bacteria suspension 0.1ml with microscale sampler spreads upon suitable culture dish surface equably.Be inverted in 37 DEG C of drying bakers and take out after 15min, object makes agar surface dry, for subsequent use.(C) paste sample scraps of paper microscale sampler to get 6 μ l testing samples (mass concentration 2mg/ml) and inject on the round filter paper of sterilizing.With aseptic nipper tweezer containing the scraps of paper of sample and the blank scraps of paper of contrast, by sterile working respectively the scraps of paper be close to containing bacterio-agar surface, paste a piece of paper sheet at a certain distance.Often kind of bacterium is cooked 3 wares, and acquired results asks its meansigma methods.(D) cultivate each plate is placed in micro-aerobic bag, sealing, opens gas generator, then is placed in 37 DEG C of incubators and cultivates 72h.(E), after surveying antibacterial circle diameter taking-up flat board, the size of antibacterial circle diameter around each scraps of paper is measured respectively.With reference to the result of matched group, the result of testing sample sensitive experiment can be drawn.In triplicate.
II. agar dilution measures MIC:(A) first compound dimethyl sulfoxide (DMSO) solution preparation of test is become the mother solution of 0.5mg/ml, then with sterilized water dilution, is finally made into 10.0 by the preparation of Drug plates, 8.0,6.0,4.5,4.0,3.5,3.0,2.5,2.0,1.5,1.0, the concentration series of 0.5 and 0.25 μ g/ml, DMSO concentration is in media as well less than 1%.The test compounds solution prepared by 1ml separately adds in the 9ml Columbia medium of 50 DEG C the horse serum that 1ml is incubated in 50 DEG C and fully mixes with being incubated, and casts in culture dish to cool.(B) experimental bacteria of transferring (being coated with bacterium) draws the 1 × 108CFU/mlHp diluted bacteria suspension 0.1ml with microscale sampler spreads upon culture dish surface equably, be inverted in 37 DEG C of drying bakers and take out after 15min, object makes agar surface dry, for subsequent use.(C) determine that test dish (contains: 85%N2 at micro-aerobic bag by MIC, 10%CO2 and 5%O2) in, be incubated 37 DEG C to cultivate 72 hours, observe Hp growing state, contrast with blank group, there is no the sample least concentration of bacteria growing completely for minimum inhibitory concentration (minimalinhibitoryconcentration, MIC) value.Positive control is ampicillin (Ampicillin).
Experiment in vitro shows, the present invention has very strong anti Helicobacter pylori activity, and it is 16mm (ATCC43504) that paper disk method shows its antibacterial circle diameter.With agar dilution display, it can suppress the growth of 5 random clinical strains (Hp001, Hp003, Hp004, Hp018 and Hp036) and 1 reference culture (ATCC43504) completely, and minimal inhibitory concentration (MIC) is 0.35g crude drug amount/ml.Make positive control with ampicillin, its Cmin (MIC) suppressed completely 6 strain test bacterium is 3.8g crude drug amount/ml.
The present invention suppresses the energy force rate ampicillin of helicobacter pylori activity strong, illustrate for the disease such as the closely-related acute and chronic gastritis of helicobacter pylori, duodenal ulcer, the present invention is the medicine of a great exploitation potential for its.It can be directly used in the treatment of corresponding disease and the preparation of related drugs.
Claims (3)
1. a rose tea, it is characterized in that, it is prepared by the raw material of following parts by weight: Flos Rosae Rugosae 18-22 part, Radix Stephaniae Japonicae 16-22 part, Chinese mugwort 10-16 part, pagoda in thousand spend 20-30 part, Radix seu caulis wrightiae pubescentis 10-14 part, drying, pulverizing, and mix homogeneously, adopt conventional production process of bagged tea again, teabag is made in pack.
2. rose tea according to claim 1, it is characterized in that, it is prepared by the raw material of following parts by weight: Flos Rosae Rugosae 120 parts, Radix Stephaniae Japonicae 18 parts, Chinese mugwort in thousand 14 parts, pagoda spends 25 parts, Radix seu caulis wrightiae pubescentis 12 parts, drying, pulverizing, and mix homogeneously, adopt conventional production process of bagged tea again, teabag is made in pack.
3. the application of rose tea in Anti-helicobacter pylori drugs as claimed in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610145262.6A CN105535171A (en) | 2016-03-14 | 2016-03-14 | Rose tea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610145262.6A CN105535171A (en) | 2016-03-14 | 2016-03-14 | Rose tea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105535171A true CN105535171A (en) | 2016-05-04 |
Family
ID=55815091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610145262.6A Withdrawn CN105535171A (en) | 2016-03-14 | 2016-03-14 | Rose tea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105535171A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106035848A (en) * | 2016-07-18 | 2016-10-26 | 安徽阜南常晖食品有限公司 | Blood-pressure-reducing health tea and preparation method thereof |
| CN113080450A (en) * | 2021-04-13 | 2021-07-09 | 花开星辰化妆品(浙江)有限公司 | Health food for inhibiting and killing helicobacter pylori and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352614A (en) * | 2014-11-26 | 2015-02-18 | 徐大东 | Medicinal tea for improving digestion |
-
2016
- 2016-03-14 CN CN201610145262.6A patent/CN105535171A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352614A (en) * | 2014-11-26 | 2015-02-18 | 徐大东 | Medicinal tea for improving digestion |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106035848A (en) * | 2016-07-18 | 2016-10-26 | 安徽阜南常晖食品有限公司 | Blood-pressure-reducing health tea and preparation method thereof |
| CN113080450A (en) * | 2021-04-13 | 2021-07-09 | 花开星辰化妆品(浙江)有限公司 | Health food for inhibiting and killing helicobacter pylori and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102824417B (en) | New method for treating helicobacter pylori related diseases | |
| CN105535171A (en) | Rose tea | |
| CN112516205A (en) | Traditional Chinese medicine composition for treating helicobacter pylori infection | |
| CN115531464A (en) | Traditional Chinese medicine composition for resisting mycoplasma ovipneumoniae and preparation method and application thereof | |
| CN102988355A (en) | Application of Aphanamixoid A for preparing helicobacter pylori resistant medicine | |
| Ugwuoji et al. | Comparative analysis of the antibacterial activities of leaf extracts of Bryophyllum pinnatum and Newbouldia laevis on clinical isolates from wound infection | |
| Jagtap et al. | FORMULATION AND DEVELOPMENT OF ANTI-ACNE SERUM USING EUPHORBIA HIRTA. | |
| Nas et al. | Phytochemical screening and antibacterial activity of Garcinia kola seed extracts against pathogenic methicillin resistant Staphylococcus aureus | |
| CN117379497B (en) | Application of traditional Chinese medicine composition in preparation of medicine for inhibiting helicobacter pylori | |
| CN103446127B (en) | Lycojaponicumin A is preparing the application in Anti-helicobacter pylori drugs | |
| CN103463023B (en) | Application of Lycojaponicumin B in helicobacter pylori resistant medicine | |
| CN102861055B (en) | Application of Houttuynoid A in helicobacter pylori resisting medicine | |
| CN102872132B (en) | Application of Houttuynoid D in anti-helicobacter pylori drug | |
| CN103550204A (en) | Application of Neonectrolide A in preparation of anti-helicobacter pylori medicaments | |
| CN104784408A (en) | Application of traditional Chinese medicine composition to preparation of anti-helicobacter pylori medicines | |
| CN103446085B (en) | Incarviatone A is preparing the application in Anti-helicobacter pylori drugs | |
| CN103356600B (en) | Chukrasone B is preparing the application in Anti-helicobacter pylori drugs | |
| Asaiya et al. | Antibacterial Effect of Pongamia pinnata Leaf Extract Against Some Human Pathogenic Bacteria | |
| CN103690527B (en) | Aphanamgrandiol A is preparing the application in Anti-helicobacter pylori drugs | |
| CN103381165B (en) | Chukrasone A is preparing the application in Anti-helicobacter pylori drugs | |
| CN114652800A (en) | External bacteriostatic lotion containing liquorice total flavonoids and preparation method thereof | |
| Agbabiaka et al. | Susceptibility of bacterial isolates of wound infections to Chromolaena odorata | |
| CN106474134A (en) | Application of the Friedolanostanes in Anti-helicobacter pylori drugs are prepared | |
| CN113144132A (en) | Traditional Chinese medicine compound extract for resisting helicobacter pylori and preparation method thereof | |
| CN107837269A (en) | Applications of the Apigenin in Anti-helicobacter pylori drugs are prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160504 |
|
| WW01 | Invention patent application withdrawn after publication |